PPARγ and the pathobiology of pulmonary arterial hypertension

Advances in Experimental Medicine and Biology

Volumn 661, Issue , 2010, Pages 447-458

  Rabinovitch, Marlene ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell proliferation and migration; Nuclear receptor; Peroxisome proliferator activated receptor (PPAR ); Pulmonary vascular remodeling

Indexed keywords

APOLIPOPROTEIN E; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLATELET DERIVED GROWTH FACTOR; ROSIGLITAZONE; BONE MORPHOGENETIC PROTEIN 2;

CELL MIGRATION; CELL PROLIFERATION; CONFERENCE PAPER; DRUG MECHANISM; DRUG TARGETING; GENE DELETION; GENE EXPRESSION REGULATION; HUMAN; HYPOXIA; INSULIN RESISTANCE; LUNG ARTERY; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; ANIMAL; CYTOLOGY; DRUG POTENTIATION; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; BONE MORPHOGENETIC PROTEIN 2; HUMANS; HYPERTENSION, PULMONARY; INSULIN RESISTANCE; MYOCYTES, SMOOTH MUSCLE; PPAR GAMMA; SIGNAL TRANSDUCTION;

EID: 77951222644     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-60761-500-2_29     Document Type: Conference Paper

References (52)

1. He W, Barak Y, Hevener A et al (2003) Adipose-specific peroxisome proliferator-activated receptor g knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A 100:15712-15717 (Pubitemid 38021055)
2. Hevener AL, He W, Barak Y et al (2003) Muscle-specific PPARg deletion causes insulin resistance. Nat Med 9:1491-1497 (Pubitemid 38004776)
3. Lehrke M, Lazar MA (2005) The many faces of PPARg. Cell 123:993-999
4. Marx N, Duez H, Fruchart JC, Staels B (2004) Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 94:1168-1178 (Pubitemid 38656403)
5. Zhang J, Fu M, Zhao L, Chen YE 2002) 15-Deoxy-prostaglandin J2 inhibits PDGF-A and -B chain expression in human vascular endothelial cells independent of PPARg. Biochem Biophys Res Commun 298:128-132 (Pubitemid 35205397)
6. Gauthier A, Vassiliou G, Benoist F, McPherson R (2003) Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferatoractivated receptor g. J Biol Chem 278:11945-11953 (Pubitemid 36800168)
7. Boucher P, Gotthardt M, Li WP, Anderson RG, Herz J (2003) LRP: role in vascular wall integrity and protection from atherosclerosis. Science 300:329-332 (Pubitemid 36433724)
8. Newton CS, Loukinova E, Mikhailenko I et al (2005) Platelet-derived growth factor receptor- b (PDGFR-b) activation promotes its association with the low density lipoprotein receptor-related protein (LRP). Evidence for co-receptor function. J Biol Chem 280: 27872-27878 (Pubitemid 41076904)
9. Wakino S, Kintscher U, Kim S, Yin F, Hsueh WA, Law RE (2000) Peroxisome proliferatoractivated receptor g ligands inhibit retinoblastoma phosphorylation and G1 → S transition in vascular smooth muscle cells. J Biol Chem 275:22435-22441 (Pubitemid 30621831)
10. Bruemmer D, Blaschke F, Law RE (2005) New targets for PPARg in the vessel wall: implications for restenosis. Int J Obes Relat Metab Disord 29:S26-S30 (Pubitemid 40343168)
11. Benkirane K, Amiri F, Diep QN, El Mabrouk M, Schiffrin EL (2006) PPAR-g inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1. Am J Physiol Heart Circ Physiol 290:H390-H397
12. Wakino S, Kintscher U, Liu Z et al (2001) Peroxisome proliferator- activated receptor g ligands inhibit mitogenic induction of p21Cip1 by modulating the protein kinase Cd pathway in vascular smooth muscle cells. J Biol Chem 276:47650-47657
13. Ogawa D, Nomiyama T, Nakamachi T et al (2006) Activation of peroxisome proliferatoractivated receptor g suppresses telomerase activity in vascular smooth muscle cells. Circ Res 98:e50-e9
14. Vantler M, Caglayan E, Zimmermann WH, Baumer AT, Rosenkranz S (2005) Systematic evaluation of anti-apoptotic growth factor signaling in vascular smooth muscle cells. Only phosphatidylinositol 3¢-kinase is important. J Biol Chem 280:14168-14176 (Pubitemid 40517319)
15. Bruemmer D, Yin F, Liu J et al (2003) Regulation of the growth arrest and DNA damageinducible gene 45 (GADD45) by peroxisome proliferator-activated receptor g in vascular smooth muscle cells. Circ Res 93:e38-e47
16. Worley JR, Baugh MD, Hughes DA et al (2003) Metalloproteinase expression in PMAstimulated THP-1 cells. Effects of peroxisome proliferator-activated receptor-g (PPARg) agonists and 9-cis-retinoic acid. J Biol Chem 278:51340-51346 (Pubitemid 38020373)
17. Nagase H, Enghild J, Suzuki K, Salvesen G (1990) Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl) mercuric acetate. Biochemistry 29:5783-5789 (Pubitemid 20192450)
18. Cowan KN, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M (2000) Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med 6:698-702 (Pubitemid 30398796)
19. Martin-Nizard F, Furman C, Delerive P et al (2002) Peroxisome proliferator-activated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells. J Cardiovasc Pharmacol 40:822-831 (Pubitemid 35365080)
20. Wakino S, Hayashi K, Tatematsu S et al (2005) Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res 28:255-262 (Pubitemid 40812611)
21. Kielstein JT, Bode-Boger SM, Hesse G et al (2005) Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 25:1414-1418 (Pubitemid 40923361)
22. Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE (2000) Inflammatory mechanisms in Alzheimer's disease: inhibition of b-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARg agonists. J Neurosci 20:558-567 (Pubitemid 30225558)
23. Humbert M, Monti G, Brenot F et al (1995) Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 151:1628-1631
24. Imaizumi T, Matsumiya T, Tamo W et al ( 2002) 15-Deoxy-D12,14- prostaglandin J2 inhibits CX3CL1/fractalkine expression in human endothelial cells. Immunol Cell Biol 80:531-536 (Pubitemid 35335015)
25. Balabanian K, Foussat A, Dorfmüller P et al (2002) CX3C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 165:1419-1425 (Pubitemid 34522947)
26. Ikeda Y, Yonemitsu Y, Kataoka C et al (2002) Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats. Am J Physiol Heart Circ Physiol 283:H2021-H2028 (Pubitemid 35217037)
27. Gensch C, Clever YP, Werner C, Hanhoun M, Böhm M, Laufs U (2007) The PPAR-g agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis 192:67-74 (Pubitemid 46628806)
28. Levonen AL, Dickinson DA, Moellering DR, Mulcahy RT, Forman HJ, Darley-Usmar VM (2001) Biphasic effects of 15-deoxy-d12,14-prostaglandin J2 on glutathione induction and apoptosis in human endothelial cells. Arterioscler Thromb Vasc Biol 21:1846-1851 (Pubitemid 34219791)
29. Cho DH, Choi YJ, Jo SA, Jo I (2004) Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) g-dependent and PPAR g-independent signaling pathways. J Biol Chem 279:2499-2506 (Pubitemid 38114233)
30. Kronke G, Kadl A, Ikonomu E et al (2007) Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol 27:1276-1282 (Pubitemid 46809415)
31. Goetze S, Xi XP, Kawano H et al (1999) PPARg-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J Cardiovasc Pharmacol 33:798-806 (Pubitemid 29196720)
32. Benson S, Wu J, Padmanabhan S, Kurtz TW, Pershadsingh HA (2000) Peroxisome proliferator- activated receptor (PPAR)-g expression in human vascular smooth muscle cells: inhibition of growth, migration, and c-fos expression by the peroxisome proliferator-activated receptor (PPAR)-g activator troglitazone. Am J Hypertens 13:74-82 (Pubitemid 30103867)
33. Law RE, Goetze S, Xi XP et al (2000) Expression and function of PPARg in rat and human vascular smooth muscle cells. Circulation 101:1311-1318 (Pubitemid 30158620)
34. Ameshima S, Golpon H, Cool CD et al (2003) Peroxisome proliferator-activated receptor g (PPARg) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ Res 92:1162-1169 (Pubitemid 36665863)
35. Geraci MW, Moore M, Gesell T et al (2001) Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis. Circ Res 88:555-562 (Pubitemid 32275790)
36. Galetto R, Albajar M, Polanco JI, Zakin MM, Rodriguez-Rey JC (2001) Identification of a peroxisome-proliferator-activated-receptor response element in the apolipoprotein E gene control region. Biochem J 357:521-527 (Pubitemid 32701790)
37. Akiyama TE, Sakai S, Lambert G et al (2002) Conditional disruption of the peroxisome proliferator- activated receptor g gene in mice results in lowered expression of ABCA1, ABCG1, and ApoE in macrophages and reduced cholesterol efflux. Mol Cell Biol 22:2607-2619 (Pubitemid 34262983)
38. Yue L, Rasouli N, Ranganathan G, Kern PA, Mazzone T (2004) Divergent effects of peroxisome proliferator-activated receptor g agonists and tumor necrosis factor a on adipocyte ApoE expression. J Biol Chem 279:47626-47632 (Pubitemid 39540908)
39. Hansmann G, Wagner RA, Schellong S et al (2007) Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-g activation. Circulation 115:1275-1284 (Pubitemid 46594772)
40. Xu A, Chan KW, Hoo RL et al (2005) Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 280:18073-18080 (Pubitemid 41389052)
41. Wang Y, Lam KS, Xu JY et al (2005) Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem 280:18341-18347 (Pubitemid 41389081)
42. Swertfeger DK, Bu G, Hui DY (2002) Low density lipoprotein receptor-related protein mediates apolipoprotein E inhibition of smooth muscle cell migration. J Biol Chem 277:4141-4146 (Pubitemid 34968674)
43. Boucher P, Gotthardt M (2004) LRP and PDGF signaling: a pathway to atherosclerosis. Trends Cardiovasc Med 14:55-60 (Pubitemid 38340847)
44. Boucher P, Liu P, Gotthardt M, Hiesberger T, Anderson RG, Herz J (2002) Platelet-derived growth factor mediates tyrosine phosphorylation of the cytoplasmic domain of the low density lipoprotein receptor-related protein in caveolae. J Biol Chem 277:15507-15513 (Pubitemid 34967817)
45. Wilkinson-Berka JL, Babic S, De Gooyer T et al (2004) Inhibition of platelet-derived growth factor promotes pericyte loss and angiogenesis in ischemic retinopathy. Am J Pathol 164:1263-1273 (Pubitemid 38387793)
46. Zamanian RT, Hansmann G, Snook S et al (2009) Insulin resistance in pulmonary arterial hypertension. Eur Respir J 33:318-324
47. Lane KB, Machado RD, Pauciulo MW et al (2000) Heterozygous germline mutations in BMPR2, encoding a TGF-b receptor, cause familial primary pulmonary hypertension. Nat Genet 26:81-84
48. Deng Z, Morse JH, Slager SL et al (2000) Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 67:737-744 (Pubitemid 30659603)
49. Machado RD, Aldred MA, James V et al (2006) Mutations of the TGF-b type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 27:121-132 (Pubitemid 43238027)
50. Atkinson C, Stewart S, Upton PD et al (2002) Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 105:1672-1678 (Pubitemid 34298611)
51. Hansmann G, de Jesus Perez VA, Alastalo TP et al (2008) An antiproliferative BMP-2/ PPARg/ApoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest 118:1846-1857 (Pubitemid 351632387)
52. Crossno JT Jr, Garat CV, Reusch JE et al (2007) Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol 292:L885-L897 (Pubitemid 46608235)